Blog
RSS FeedPosted by Michael Wonder on 12 Apr 2023
ASCO policy statement on biosimilar and interchangeable products in oncology
12 April 2023 - Given the current market dynamics and the regulatory landscape, this ASCO manuscript now seeks to propose several ...
Posted by Michael Wonder on 01 Apr 2023
Outcome statement - February 2023 DUSC meeting
31 March 2023 - The outcome statement from the February 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 26 Dec 2022
Boom in scripts to fight depression
22 December 2022 - The explosion in popularity of the drugs comes despite warnings from psychiatrists that antidepressants should not be ...
Posted by Michael Wonder on 03 Nov 2022
Outcome statement - September 2022 DUSC meeting
3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 25 Oct 2022
DUSC utilisation analysis public release documents (October 2022)
25 October 2022 - The utilisation analysis public release documents from the June 2022 DUSC meeting are now available. ...
Posted by Michael Wonder on 24 Oct 2022
Saskatchewan becomes sixth Canadian province to implement a biosimilar switching policy
21 October 2022 - Saskatchewan joined five provinces and one territory in implementing a biosimilar switching policy, allowing for reference ...
Posted by Michael Wonder on 13 Oct 2022
Amgen's annual trends report finds competition created by biosimilars contributed $21 billion in US health care system savings
12 October 2022 - Ninth Edition of Amgen's Biosimilar Trends Report Examines the U.S. and Global Marketplace with Biosimilars. ...
Posted by Michael Wonder on 05 Oct 2022
Continued development of the national health data registers leads to better follow-up of medicines
3 October 2022 - The Dental and Pharmaceutical Benefits Agency (TLV) is today handing over a report to the government on ...
Posted by Michael Wonder on 26 Sep 2022
Novavax appeals to ATAGI to change advice as vaccine uptake falls behind
25 September 2022 - Novavax was hailed as the fix to Australia’s low inoculation rate and “the vaccine for anti-vaxxers”. So ...
Posted by Michael Wonder on 22 Sep 2022
13 million Novavax doses due to expire as Australians stick to mRNA boosters
21 September 2022 - Novavax COVID vaccines procured by the federal government in the hopes of convincing hesitant Australians to ...
Posted by Michael Wonder on 31 Aug 2022
Pharmaceutical Benefits Scheme supplied medications
30 August 2022 - Key findings about health and population characteristics from the National Health Survey (NHS) and the Pharmaceutical Benefits ...
Posted by Michael Wonder on 03 Aug 2022
U.S. prescription drug market lacks certain competitive features: case of biosimilars
3 August 2022 - In a legal ruling reported yesterday, a 7th Circuit Court Federal Judge, Frank Easterbrook, affirmed dismissal of ...
Posted by Michael Wonder on 13 Jul 2022
Biosimilar uptake accelerates in US—and so do the savings
13 July 2022 - Amgen's early view said health care savings from the use of these biologic therapies climbed to ...
Posted by Michael Wonder on 11 Jul 2022
Drug Utilisation SubCommittee outcome statement
8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 03 Jul 2022
NHS saves 1.2 billion pounds on medicines over three years
1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...